NEOGENOMICS INC
For the period ended Dec 31, 2023. Filed Feb 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 20, 2024
NEO$16.96-3.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, 202 and
| Table of Contents | NEOGENOMICS, INC. |
|---|
(In thousands, except share and per share amounts)
| As of December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $342,488 | $263,180 |
| Marketable securities, at fair value | 72,715 | 174,809 |
| Accounts receivable, net | 131,227 | 119,711 |
| Inventories | 24,156 | 24,277 |
| Prepaid assets | 17,987 | 15,237 |
| Other current assets | 8,239 | 8,077 |
| Total current assets | 596,812 | 605,291 |
| Property and equipment (net of accumulated depreciation of $158,211 and $131,930, respectively) | 92,012 | 102,499 |
| Operating lease right-of-use assets | 91,769 | 96,109 |
| Intangible assets, net | 373,128 | 408,260 |
| Goodwill | 522,766 | 522,766 |
| Other assets | 4,742 | 5,109 |
| Total non-current assets | 1,084,417 | 1,134,743 |
| Total assets | $1,681,229 | $1,740,034 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Accounts payable | $20,334 | $20,510 |
| Accrued compensation | 53,161 | 40,141 |
| Accrued expenses and other liabilities | 15,069 | 15,070 |
| Current portion of equipment financing obligations | — | 70 |
| Current portion of operating lease liabilities | 5,610 | 6,584 |
| Contract liabilities | 2,130 | 7,557 |
| Total current liabilities | 96,304 | 89,932 |
| Long-term liabilities | ||
| Convertible senior notes, net | 538,198 | 535,322 |
| Operating lease liabilities | 67,871 | 68,952 |
| Deferred income tax liabilities, net | 24,285 | 34,750 |
| Other long-term liabilities | 13,034 | 13,055 |
| Total long-term liabilities | 643,388 | 652,079 |
| Total liabilities | 739,692 | 742,011 |
| Commitments and contingencies (Note 15) | ||
| Stockholders’ equity | ||
| Common stock, $0.001 par value, (250,000,000 shares authorized; 127,369,142 and 126,913,992 shares issued and outstanding, respectively) | 127 | 127 |
| Additional paid-in capital | 1,190,139 | 1,160,882 |
| Accumulated other comprehensive loss | (1,674) | (3,899) |
| Accumulated deficit | (247,055) | (159,087) |
| Total stockholders’ equity | 941,537 | 998,023 |
| Total liabilities and stockholders’ equity | $1,681,229 | $1,740,034 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.